Elderdery A, Idris H, Alruwaili S, Tebien E, Alsrhani A, Alenazy F
Int J Mol Sci. 2025; 25(24.
PMID: 39769254
PMC: 11728260.
DOI: 10.3390/ijms252413493.
Fadul A, Abdalla E, Mohamed A, Ali B, Elamin N, Alsayed A
J Blood Med. 2025; 15:549-556.
PMID: 39741578
PMC: 11687131.
DOI: 10.2147/JBM.S474393.
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A
Br J Haematol. 2024; 205(6):2295-2304.
PMID: 39506529
PMC: 11637719.
DOI: 10.1111/bjh.19819.
Darba J, Ascanio M, Aguera A
Eur J Health Econ. 2024; .
PMID: 39340748
DOI: 10.1007/s10198-024-01727-6.
Deshpande A, Osman D, Murthy V, Hussein H
EJHaem. 2024; 5(4):859-862.
PMID: 39157620
PMC: 11327750.
DOI: 10.1002/jha2.967.
Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.
George B, Chan K, Rios A
Front Oncol. 2024; 14:1446517.
PMID: 39139284
PMC: 11320603.
DOI: 10.3389/fonc.2024.1446517.
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.
Eshaq A, Flanagan T, Hassan S, Al Asheikh S, Al-Amoudi W, Santourlidis S
Cancers (Basel). 2024; 16(15).
PMID: 39123481
PMC: 11311543.
DOI: 10.3390/cancers16152754.
Exploring treatment decision-making in chronic myeloid leukemia in chronic phase.
Andorsky D, Kota V, Sweet K
Front Oncol. 2024; 14:1369246.
PMID: 39011484
PMC: 11246988.
DOI: 10.3389/fonc.2024.1369246.
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.
Fernando F, Andres M, Claudiani S, Kermani N, Ceccarelli G, Innes A
Cardiooncology. 2024; 10(1):42.
PMID: 39010172
PMC: 11247904.
DOI: 10.1186/s40959-024-00245-x.
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
Tian J, Song Y, Zhang G, Wang S, Chu X, Chai Y
J Cancer Res Clin Oncol. 2024; 150(4):189.
PMID: 38605258
PMC: 11009770.
DOI: 10.1007/s00432-024-05700-x.
HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR.
Rinaldi I, Mauludi R, Jusman S, Sinto R, Harimurti K
J Blood Med. 2024; 15:61-67.
PMID: 38375065
PMC: 10875243.
DOI: 10.2147/JBM.S436015.
Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review.
Li Y, Zhang Y, Meng X, Chen S, Wang T, Zhang L
Medicine (Baltimore). 2024; 103(3):e36728.
PMID: 38241589
PMC: 10798786.
DOI: 10.1097/MD.0000000000036728.
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R
Ther Adv Hematol. 2023; 14:20406207221150305.
PMID: 38105770
PMC: 10725100.
DOI: 10.1177/20406207221150305.
Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials.
Salama M, Aborehab N, El Mahdy N, Zayed A, Ezzat S
Eur J Med Res. 2023; 28(1):566.
PMID: 38053150
PMC: 10696888.
DOI: 10.1186/s40001-023-01539-z.
Gingival Enlargement Can Constitute the Only Diagnostic Sign of Leukemia: Report of an Unusual Case.
Zisis V, Zisis S, Anagnostou E, Dabarakis N, Poulopoulos A, Andreadis D
Cureus. 2023; 15(10):e47959.
PMID: 38034185
PMC: 10685703.
DOI: 10.7759/cureus.47959.
Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia.
Janani G, Girigoswami A, Girigoswami K
ADMET DMPK. 2023; 11(4):499-511.
PMID: 37937247
PMC: 10626512.
DOI: 10.5599/admet.2013.
The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa.
Hoosen S, Mackraj I, Rapiti N
Adv Hematol. 2023; 2023:2004135.
PMID: 37547186
PMC: 10403330.
DOI: 10.1155/2023/2004135.
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C
Cells. 2023; 12(13).
PMID: 37443737
PMC: 10341256.
DOI: 10.3390/cells12131703.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Shah N, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, Saussele S, Rea D
Br J Haematol. 2023; 202(5):942-952.
PMID: 37246588
PMC: 10524617.
DOI: 10.1111/bjh.18883.
Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.
Rinaldi I, Winston K
J Blood Med. 2023; 14:261-277.
PMID: 37051025
PMC: 10084831.
DOI: 10.2147/JBM.S382090.
